Key Takeaways
- • A California federal jury acquitted Armistice Capital and two of its executives on all class action claims alleging securities fraud, pump-and-dump manipulation, and insider trading involving $250 million in Vaxart stock during the COVID-19 pandemic.
- • The verdict eliminates litigation risk for Armistice Capital and resolves allegations that the hedge fund used misleading press releases to artificially inflate and then sell down Vaxart positions during the pandemic period.
- • The defense successfully countered plaintiff arguments that Vaxart's announcements were materially false, positioning disclosed statements as "true and accurate" in closing arguments.
- • This outcome represents a significant legal victory for alternative asset managers facing securities litigation tied to pandemic-era trading activity and reduces precedential exposure for similar pump-and-dump allegations in the hedge fund space.
Summary
A California federal jury on Tuesday, April 28, 2026, cleared Armistice Capital and two of its executives of all class action allegations alleging securities fraud, pump-and-dump manipulation, and insider trading related to approximately $250 million in Vaxart stock transactions during the COVID-19 pandemic. The verdict concludes litigation that centered on whether the hedge fund employed misleading corporate announcements to artificially elevate Vaxart's share price before liquidating its positions.
During closing arguments the prior evening, plaintiffs' counsel characterized Armistice Capital's conduct as pandemic-era "greed," asserting that the hedge fund deployed false or misleading press releases to manipulate Vaxart's stock valuation. In contrast, defense counsel argued that Vaxart's public statements were factually "true and accurate," directly challenging the materiality and falsity prongs required under federal securities law. The jury's verdict sided with the defense position across all counts.
The acquittal carries substantial implications for institutional investors and hedge fund managers facing securities litigation tied to pandemic-period trading strategies. By clearing Armistice Capital on the core allegations of market manipulation and insider trading violations, the jury's decision reduces litigation precedent that might otherwise have exposed alternative managers to expanded liability standards. The case underscores the evidentiary bar required to establish securities fraud in pump-and-dump schemes, particularly where defendant communications can be positioned as substantially consistent with corporate disclosures.
During closing arguments the prior evening, plaintiffs' counsel characterized Armistice Capital's conduct as pandemic-era "greed," asserting that the hedge fund deployed false or misleading press releases to manipulate Vaxart's stock valuation. In contrast, defense counsel argued that Vaxart's public statements were factually "true and accurate," directly challenging the materiality and falsity prongs required under federal securities law. The jury's verdict sided with the defense position across all counts.
The acquittal carries substantial implications for institutional investors and hedge fund managers facing securities litigation tied to pandemic-period trading strategies. By clearing Armistice Capital on the core allegations of market manipulation and insider trading violations, the jury's decision reduces litigation precedent that might otherwise have exposed alternative managers to expanded liability standards. The case underscores the evidentiary bar required to establish securities fraud in pump-and-dump schemes, particularly where defendant communications can be positioned as substantially consistent with corporate disclosures.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.